InMed Pharmaceuticals News | Press Releases

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Menu

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Press Releases

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

September 29, 2023

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

September 22, 2023

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

September 7, 2023

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

July 21, 2023

InMed Provides Update on BayMedica Rare Cannabinoid Business

July 20, 2023

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

June 22, 2023

InMed’s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

June 1, 2023

InMed to Participate in Upcoming Virtual Investor Events

May 24, 2023

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

May 18, 2023

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

May 15, 2023

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

March 28, 2023

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

March 13, 2023

InMed to Participate in Upcoming Investor Events

March 7, 2023

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023

InMed Submits Form 12b-25

February 9, 2023

InMed Provides Business Update and Milestones for 2023

January 10, 2023

InMed Announces Results of 2022 Annual General Meeting

December 15, 2022

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

December 12, 2022

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

November 21, 2022

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

November 18, 2022

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Next »

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
INM-900 Series for Neurodegenerative Disease
Novel Cannabinoid Analogs

MANUFACTURING

BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media & Videos
Investor Contact

CORPORATE

Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent*

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.

CAPTCHA